Lilly shares jumped 6% to a record high Thursday after earnings beat expectations, with weight loss drug sales leading the way.
Recap by typeshit. Full story at New York Post on MSN.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Western Isles prescribes at 10 times Shetland's rate, and 71% of Scots who used weight loss drugs in the past year got them privately, the ABPI reports.
A retail trade report maps out the points where grocers can connect with shoppers taking GLP-1 drugs.
Loading…